FDA
-
-
-
-
-
-
-
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
-
-
-
-
-
-
-
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
-
-
-
-
-
-
-
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
-
-
-
-
-
-
-
INmune Bio to present Phase 2 Alzheimer's trial data at conference
-
-
-
-
-
-
-
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
-
-
-
-
-
-
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
-
-
-
-
-
-
-
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

